title: First human studies with a high-molecular-weight iron chelator.
abstract: The release of free, reactive iron from cellular iron stores has been implicated as an important contributor to tissue damage in a variety of clinical situations, including ischemia and reperfusion injury, hemorrhagic shock, and burn injury. Deferoxamine mesylate (DFO), the only iron chelator currently approved for clinical use, is used for the treatment of iron overload, including acute iron poisoning and treatment of chronic iron overload in transfusion-dependent anemias such as beta-thalassemia. However, it is not suitable for acute care situations because of its toxicity, primarily hypotension when given at high intravenous doses, and its short plasma half-life. We have produced a high-molecular-weight iron chelator by chemically coupling DFO to hydroxyethyl starch. This novel chelator (HES-DFO) was administered to healthy male subjects by intravenous infusion over a 4-hour period. The drug was well tolerated, and signs of DFO acute toxicity were not observed. Maximum plasma chelator levels of approximately 3 mmol/L were achieved with HES-DFO, which is more than an order of magnitude higher than has been reported with injections of DFO. Drug residence time in plasma was markedly prolonged, with an initial half-life of 22 to 33 hours. Urinary iron excretion was 7.1 +/- 2.2 mg in 48 hours in the highest dose group, as compared with 0.06 +/- 0.15 mg in control subjects who received normal saline infusions. Intravenous infusion of HES-DFO is well tolerated, produces substantial and prolonged plasma chelator levels, and markedly stimulates urinary iron excretion.
authors.affiliation: Biomedical Frontiers Inc, Minneapolis, Minnesota, 55414, USA.
authors.forename: P R
authors.initials: PR
authors.lastname: Dragsten
authors.forename: P E
authors.initials: PE
authors.lastname: Hallaway
authors.forename: G J
authors.initials: GJ
authors.lastname: Hanson
authors.forename: A E
authors.initials: AE
authors.lastname: Berger
authors.forename: B
authors.initials: B
authors.lastname: Bernard
authors.forename: B E
authors.initials: BE
authors.lastname: Hedlund
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003676:Deferoxamine / Q000737:chemistry / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000737:chemistry / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D007501:Iron / Q000652:urine; D007502:Iron Chelating Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D008297:Male; D008970:Molecular Weight
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D007502:Iron Chelating Agents; C068460:hydroxyethyl starch-deferoxamine conjugate; D007501:Iron; D003676:Deferoxamine